{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011975","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.165991+00:00","generated_at":"2026-05-17T13:07:00.856674+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025","bullets":["Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.","Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.","Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.","Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.","Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011975","json":"https://secwatch.observer/filing/0001493152-25-011975.json","markdown":"https://secwatch.observer/filing/0001493152-25-011975.md","text":"https://secwatch.observer/filing/0001493152-25-011975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315225011975/0001493152-25-011975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315225011975/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:07:00.856674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}